NAMS
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- NewAmsterdam Pharma doses the first participant in the Phase 2b SPINOZA trial evaluating obicetrapib in preclinical Alzheimer’s diseaseSep 29, 2026
- NewAmsterdam Pharma and Menarini Group receive European Commission approval for Ubeslo (obicetrapib monotherapy) and Evlarco (obicetrapib plus ezetimibe)Sep 21, 2026
- NewAmsterdam Pharma and Menarini receive positive CHMP opinion for Ubeslo and Evlarco cholesterol treatmentsJul 24, 2026
- NewAmsterdam Pharma presents positive data from BROADWAY trial showing significant reductions in key Alzheimer's disease biomarkers at AAIC 2025Jul 30, 2025
- NewAmsterdam Pharma announces positive Alzheimer’s data from BROADWAY trialJun 9, 2025